Vitiligo During Melanoma Immunotherapy — Is It a Good Sign?

Most people diagnosed with melanoma never receive immunotherapy. A melanoma found early is removed by surgery and nothing is given afterwards. Immunotherapy has a defined role in melanoma that has spread and cannot be removed, and in a selected group at high risk of the melanoma returning after surgery. Everything below assumes you are already in that smaller group.

Medical history narrows it further. Active autoimmune disease, an organ transplant, or ongoing high-dose steroids can make checkpoint inhibitor immunotherapy unsuitable or higher-risk. The treatment works by loosening restraints on the immune system rather than by attacking the tumour directly, so an immune system already acting against the body is a genuine problem, not a technicality.

There is an Indian caveat worth carrying into the rest of this page. Melanoma here far more often starts on the sole of the foot, the palm, under a nail, or on an internal lining such as the mouth or nose. Those subtypes are not caused by ultraviolet damage, and guideline bodies report that they respond less well than the sun-driven melanoma most published data comes from.

Nothing on this page decides eligibility. That rests on the biopsy report, the stage, previous treatment and overall fitness, read together by a medical oncologist. Immunotherapy at CION Cancer Clinics sets out how the treatment is delivered and monitored across our centres.

Because melanoma cells and the healthy pigment cells in your skin carry the same surface proteins. Immunotherapy removes the brakes on immune cells so that they act against those proteins. The immune system cannot tell a melanoma cell from a normal melanocyte. Pigment cells in ordinary skin are destroyed alongside the cancer, and the skin above them turns white.

The proteins involved are the pigment-making ones, with names such as tyrosinase and MART-1. They are what makes melanoma recognisable to immune cells in the first place. They are also what makes the melanocyte in your forearm recognisable. The same accuracy that lets the treatment find melanoma deposits is what produces the patches, which is why oncologists describe depigmentation as collateral evidence of an immune response rather than as a malfunction.

This is close to melanoma-specific. Checkpoint inhibitor immunotherapy is used in many cancers, but vitiligo-like depigmentation is reported chiefly in melanoma, because melanoma is the only common cancer that arises from pigment cells. If a friend on the same class of treatment for a lung or kidney cancer has no such patches, that is expected, not a difference in how well it is working.

What it looks like is fairly consistent. Patches are flat, sharply edged, milk-white rather than pale, and usually symmetrical — both hands, both forearms, around the eyes and mouth, or on the trunk. They are typically painless and do not itch. Some people also notice hair, eyebrows or eyelashes turning white in the same areas, which is called poliosis and is part of the same process.

Timing is variable and rarely immediate. Most people notice the first patch some weeks to months after starting, commonly after several cycles rather than after the first one, and new areas can keep appearing for as long as treatment continues. Depigmentation is not a reaction to a single dose, so it is not something you can trace back to one bad infusion.

One point that matters in India: this is not contagious, it is not leprosy, and it is not caused by anything you ate or did. If a family member says otherwise, bring them to the next consultation and let the oncologist say it.

It is generally taken as an encouraging sign, but it is not a test result. Across published melanoma series, patients who develop vitiligo-like depigmentation have more often been in the group whose melanoma responded. That is an association observed in a population. It is not a prediction for one person, and no percentage can honestly be attached to it.

The table below is the useful version of that answer. Read the right-hand column, not just the middle one — what a skin sign does not tell you is more decision-relevant than what it does.

Two practical consequences follow. First, treatment is never continued or stopped because of white patches. Immunotherapy is given as day care at CION centres on a set schedule, and the decision to carry on comes from the assessment scan, coordinated at partner imaging centres, read together with how you are clinically. Second, if you are watching your skin every morning hoping for a sign, say so at your next visit. That is an extremely common way to spend the months between scans, and it is worth naming rather than carrying alone.

Be wary of any page or forum post that converts this association into a survival number for an individual. It cannot be done honestly, and current NCCN and ESMO guidance, as of August 2026, does not use depigmentation as a biomarker for treatment decisions.

Usually, yes. Once the pigment cells in an area of skin have been destroyed, there is no reservoir left to repopulate it, so the patch generally stays white. Some partial repigmentation has been reported after treatment ends, but it is uncommon and unpredictable. Plan for sun protection and camouflage rather than waiting for the colour to return.

The pattern usually settles rather than reverses. New patches tend to keep appearing while treatment continues and then stop appearing once it does, which is often the first thing people notice about the timeline. Long-term follow-up of this specific effect is thinner than patients expect, because it was recorded for years as a minor cosmetic footnote to trials designed to measure something else. Anyone who tells you exactly how your skin will look in five years is going beyond the evidence.

Treating it is a genuinely different conversation from treating ordinary vitiligo, for two reasons. The creams normally used damp down the immune response in the skin, and they are being considered in someone whose cancer treatment depends on that immune response — a trade-off to be weighed by your oncologist and a dermatologist together, not assumed. More importantly, narrowband ultraviolet phototherapy, the mainstay for ordinary vitiligo, means deliberate ultraviolet exposure in a person who has already had melanoma. It is generally avoided, or used only with great caution, for that reason.

Depigmented skin also has no melanin protection, so it burns quickly and it burns badly. This matters more here than in ordinary vitiligo, because the person it is happening to has already had a melanoma. Daily broad-spectrum sunscreen on exposed patches, long sleeves, and a hat are not cosmetic advice on this page. They are part of the treatment plan, and they continue after immunotherapy ends.

Never start a cream, a supplement or a light treatment for depigmentation on your own, and tell any dermatologist you consult that you are on or have had immunotherapy for melanoma. It changes what is safe to offer you.

• Tell the treating team, and photograph the patches. A dated photo in good daylight, taken every few weeks from the same distance, is more useful than any description. It lets the team see whether the pattern is stable or spreading without relying on memory between visits.
• Protect the depigmented skin from sun, every day. Broad-spectrum sunscreen, long sleeves and a hat, including on cloudy days and on short outdoor errands. Skin without pigment has no built-in protection, and this is skin on a person who has already had a melanoma.
• Do not change your treatment because of it. Painless depigmentation is rarely a reason to interrupt or stop, and its appearance is equally not a reason to ask for more treatment. Those decisions belong to the scan and the tumour board.
• Ask about camouflage rather than assuming there is nothing. Skin-tone-matched cover creams and self-tanning preparations are used for ordinary vitiligo and work the same way here. A dermatologist can match a shade properly, which matters more on brown skin than the general advice online suggests.
• Report eye or hearing symptoms the same day. Blurred vision, eye pain or redness, new hearing loss or ringing in the ears alongside depigmentation are uncommon but need urgent assessment, not a wait-and-see. Call the treating team or the CION helpline on 1800 202 8726 rather than waiting for the next scheduled visit.

There is a part of this that no clinical grading scale captures. Depigmentation is graded as one of the mildest immune-related effects, which is medically accurate and emotionally useless if you are twenty-nine, back at work, and answering questions about your hands every day. In India that lands harder still, because vitiligo carries a social weight that has nothing to do with cancer — questions about marriage, misplaced worry about contagion, confusion with leprosy. None of it is medically true. All of it is real to live with.

Say so at your consultation. CION consultations run 45 minutes precisely so that this kind of thing has room, and psycho-oncology support is part of the service, not an add-on you have to justify asking for. A treatment effect being minor on a chart does not make it minor in your life, and no oncologist worth consulting will treat it as a trivial complaint.

• If the patches have you thinking about the years ahead, that is the right instinct — Long-Term Survivors of Melanoma Immunotherapy: What Happens Next covers what follow-up, scanning and skin surveillance actually look like once treatment ends.
• The other question that arrives early is what a course costs and what schemes cover — Cost of Melanoma Immunotherapy in India sets out indicative figures as of August 2026 rather than a single headline number.
• To see how differently the same class of treatment is used in a cancer that has nothing to do with pigment cells, and why depigmentation is not expected there, read Immunotherapy for Nasopharyngeal Cancer.
• For how immunotherapy is delivered, monitored and paid for across our centres, see Immunotherapy at CION Cancer Clinics.

Still unsure whether what you are seeing is this or something else? Book a free consultation and a medical oncologist will look at it against your treatment record.